All Stories

  1. Uric acid and alterations of purine recycling disorders in Parkinson’s disease: a cross-sectional study
  2. Enzymatic properties and clinical associations of serum alpha‐galactosidase A in Parkinson's disease
  3. Sphingolipid abnormalities in encephalomyeloradiculoneuropathy (EMRN) are associated with an anti‐neutral glycolipid antibody
  4. A pilot study assessing sphingolipids and glycolipids dysmetabolism in idiopathic normal pressure hydrocephalus
  5. Ceramides accumulation and complement activation in patients with EMRN
  6. Piroheptine for Treating Parkinson
  7. Mazaticol for Treating Parkinson
  8. Acknowledgments
  9. Detection of human herpesviruses in cerebrospinal fluids collected from patients suspected of neuroinfectious diseases
  10. Detection of circulating tumor DNA in cerebrospinal fluid prior to diagnosis of spinal cord lymphoma by flow cytometric and cytologic analyses
  11. Corrigendum to “Galabiosylceramide is present in human cerebrospinal fluid”
  12. Cerebrospinal Fluid Profiles in Parkinson’s Disease: No Accumulation of Glucosylceramide, but Significant Downregulation of Active Complement C5 Fragment
  13. Review article for the close relationship between neuroinflammation and glycosphingolipids
  14. Galabiosylceramide is present in human cerebrospinal fluid
  15. Clioquinol kills astrocyte-derived KT-5 cells by the impairment of the autophagy–lysosome pathway
  16. Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-Barré syndrome
  17. cross-talk between Trk neurotrphin receptor and innate immunity
  18. Variants in saposin D domain of prosaposin gene linked to Parkinson’s disease
  19. Mazaticol for Treating Parkinson
  20. Better neuroradiological approach for the diagnosis of early-stage Parkinson's disease patients
  21. Piroheptine for Treating Parkinson
  22. Altered regulation of serum lysosomal acid hydrolase activities in Parkinson's disease: A potential peripheral biomarker?
  23. A Patient With Thiamine Deficiency Exhibiting Muscle Edema Suggested by MRI
  24. Changes in Serial D-Dimer Levels Predict the Prognoses of Trousseau's Syndrome Patients
  25. Anti-GM1 ganglioside antibodies modulate membrane-associated sphingomyelin metabolism by altering neutral sphingomyelinase activity
  26. Markers for Guillain-Barré syndrome with poor prognosis: a multi-center study
  27. Usefulness of combining 123 I-FP-CIT-SPECT striatal asymmetry index and cardiac 123 I-metaiodobenzylguanidine scintigraphy examinations for diagnosis of parkinsonisms
  28. MR neurography for the evaluation of CIDP
  29. Differentiation of cancer from atrial fibrillation in patients with acute multifocal stroke
  30. encephalomyeloradiculoneuropathy patient showing anti-neutral glycolipids antibodies and epilepsy
  31. brain abscess
  32. Retrospective analysis of parkinsonian patients exhibiting normal 123I-MIBG cardiac uptake
  33. Voriconazole-responsive Disseminated Nodular Lesions on Spinal MRI
  34. Neurotropin promotes NGF signaling through interaction of GM1 ganglioside with Trk neurotrophin receptor in PC12 cells
  35. Hypertrophic pachymeningitis and encephalitis in a patient with relapsing polychondritis
  36. An update on diagnostic imaging studies for viral encephalitis
  37. Winged scapula in patients with myotonic dystrophy type 1
  38. Extracorporeal Aβ removal system (EARS) for Alzheimer's disease therapy: Novel devices with fragments of hollow fibers removed Aβ effectively both in vitro and in vivo
  39. Glycobiology and neurological disorders
  40. Transient Splenial Lesion of the Corpus Callosum in H1N1 Influenza Virus-Associated Encephalitis/Encephalopathy
  41. Neurotrophin Levels in Cerebrospinal Fluid of Adult Patients with Meningitis and Encephalitis
  42. Stimulated neuronal expression of brain-derived neurotrophic factor by Neurotropin
  43. Novel therapeutic approach for Alzheimer’s disease by removing amyloid β protein from the brain with an extracorporeal removal system
  44. Muscle MRI in Myotonic Dystrophy Type 1 with Foot Drop
  45. Clioquinol inhibits NGF-induced Trk autophosphorylation and neurite outgrowth in PC12 cells
  46. Toward the novel method of treatment for Alzheimer's disease: Extra-corporeal Aβ removal system (EARS)
  47. Electroretinograms in three cases of Creutzfeldt-Jakob disease with visual disturbances
  48. Acute Autonomic, Sensory and Motor Neuropathy: Successful Treatment with IVIg
  49. β-amyloid (25–35) enhances lipid metabolism and protein ubiquitination in cultured neurons
  50. Role of Glycosphingolipids and Therapeutic Perspectives on Alzheimers Disease
  51. Postinfectious Myeloradiculoneuropathy With Cranial Nerve Involvements Associated With Human Herpesvirus 7 Infection
  52. Impairment of Trk-Neurotrophin Receptor by the Serum of a Patient With Subacute Sensory Neuropathy
  53. Abnormal intracellular trafficking of high affinity nerve growth factor receptor, Trk, in stable transfectants expressing presenilin 1 protein
  54. Tyrosine phosphorylation of the catalytic subunit p110 of phosphatidylinositol-3 kinase induced by HMG-CoA reductase inhibitor inhibits its kinase activity in L6 myoblasts
  55. Biological Implication of the Membrane Rafts in Neuronal Cells
  56. Spinal Cavitous Hemorrhagic Infarction with Abdominal Aortic Aneurysm
  57. HMG-CoA reductase inhibitor induces a transient activation of high affinity nerve growth factor receptor, Trk, and morphological differentiation with fatal outcome in PC12 cells
  58. Posterior Thoracic Spinal Cord Infarction: Complication of Thoracoabdominal Aortic Aneurysm
  59. MRI findings of benign monomelic amyotrophy of lower limb
  60. Role of tyrosine phosphorylation of phospholipase C γ1 in the signaling pathway of HMG-CoA reductase inhibitor-induced cell death of L6 myoblasts
  61. Involvement of tyrosine phosphorylation in HMG-CoA reductase inhibitor-induced cell death in L6 myoblasts
  62. Expression of GDNF receptor (RET and GDNFR-α) mRNAs in the spinal cord of patients with amyotrophic lateral sclerosis
  63. Influence of endogenous GM1 ganglioside on TrkB activity, in cultured neurons
  64. HMG-CoA reductase inhibitor-induced L6 myoblast cell death: involvement of the phosphatidylinositol 3-kinase pathway
  65. Differential signaling cascade of MAP kinase and S6 kinase depends on 3′,5′-monophosphate concentration in Schwann cells: correlation to cellular differentiation and proliferation
  66. NGF prevention of neurotoxicity induced by cisplatin, vincristine and taxol depends on toxicity of each drug and NGF treatment schedule:
  67. GM1 gangliosidosis type 3 with severe jaw-closing impairment
  68. Chorea-acanthocytosis with polyclonal antibodies to ganglioside GM1
  69. Discovery of ganglioside GM1 for normal function of Trk neurotrophin receptor in neuronal cells.
  70. 1-Methyl-4-phenylpyridinum kills differentiated PC12 cells with a concomitant change in protein phosphorylation
  71. Abundant but Inactive-state gpl40prototrkIs Expressed in Neuroblastomas of Patients with Good Prognosis
  72. The Effect of the B Subunit of Cholera Toxin on the Action of Nerve Growth Factor on PC12 Cells
  73. A microassay for acid β-galactosidase activity toward asialofetuin
  74. Application of a GM1 ganglioside β-galactosidase microassay method to diagnosis of GM1 gangliosidosis
  75. A fluorometric microassay procedure for monitoring the enzymatic activity of GM1-ganglioside β-galactosidase by use of high-performance liquid chromatography